Overview

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc